Stability of c-K-ras amplification during progression in a patient with adenocarcinoma of the ovary - PubMed (original) (raw)
. 1985 Sep;45(9):4468-72.
- PMID: 4028028
Stability of c-K-ras amplification during progression in a patient with adenocarcinoma of the ovary
J E Filmus et al. Cancer Res. 1985 Sep.
Abstract
We have identified a case of serous cystadenocarcinoma of the ovary in which the tumor cells display an amplification (from 10- to 20-fold) of the cellular oncogene K-ras. Normal cells purified from the malignant ascites did not show such amplification. Five consecutive samples were obtained by paracentesis over a 9-month period during which the patient received chemotherapy and underwent clinical progression. The level of c-K-ras amplification in the tumor cells did not change during this period. In studies of the tumors of 6 additional patients with adenocarcinoma of the ovary and 5 cell lines of the same histology, we have detected no other example of significant c-K-ras amplification.
Similar articles
- A cell line from a human ovarian carcinoma with amplification of the K-ras gene.
Filmus J, Trent JM, Pullano R, Buick RN. Filmus J, et al. Cancer Res. 1986 Oct;46(10):5179-82. Cancer Res. 1986. PMID: 3756872 - [A study of amplifications of myc gene (c-myc and N-myc) in human ovarian cancer].
Kataoka A, Yakushiji M, Kojiro M. Kataoka A, et al. Nihon Sanka Fujinka Gakkai Zasshi. 1990 Mar;42(3):259-63. Nihon Sanka Fujinka Gakkai Zasshi. 1990. PMID: 2332674 Japanese. - [ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization].
Zhong M, Li J, Ding YQ, Song LL. Zhong M, et al. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006 Dec;23(6):665-7. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006. PMID: 17160949 Chinese. - Establishment and characterization of a serous papillary adenocarcinoma cell line of the human ovary in a serum-free culture.
Emoto M, Oshima K, Ishiguro M, Iwasaki H, Kawarabayashi T, Kikuchi M. Emoto M, et al. Pathol Res Pract. 1999;195(4):237-42. Pathol Res Pract. 1999. PMID: 10337661 - Comparative properties of five human ovarian adenocarcinoma cell lines.
Buick RN, Pullano R, Trent JM. Buick RN, et al. Cancer Res. 1985 Aug;45(8):3668-76. Cancer Res. 1985. PMID: 4016745
Cited by
- RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Fang B. Fang B. Acta Biochim Biophys Sin (Shanghai). 2016 Jan;48(1):27-38. doi: 10.1093/abbs/gmv090. Epub 2015 Sep 7. Acta Biochim Biophys Sin (Shanghai). 2016. PMID: 26350096 Free PMC article. Review. - Predictive biomarkers in precision medicine and drug development against lung cancer.
Fang B, Mehran RJ, Heymach JV, Swisher SG. Fang B, et al. Chin J Cancer. 2015 Jul 2;34(7):295-309. doi: 10.1186/s40880-015-0028-4. Chin J Cancer. 2015. PMID: 26134262 Free PMC article. Review. - Genetic Interactions of STAT3 and Anticancer Drug Development.
Fang B. Fang B. Cancers (Basel). 2014 Mar 6;6(1):494-525. doi: 10.3390/cancers6010494. Cancers (Basel). 2014. PMID: 24662938 Free PMC article. - In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies.
McDermott M, Eustace AJ, Busschots S, Breen L, Crown J, Clynes M, O'Donovan N, Stordal B. McDermott M, et al. Front Oncol. 2014 Mar 6;4:40. doi: 10.3389/fonc.2014.00040. eCollection 2014. Front Oncol. 2014. PMID: 24639951 Free PMC article. - BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, Thery J, Williams D, Potter J, Tran T, Korpanty G, Cremona M, Carey M, Li J, Li Y, Aslan O, O'Leary JJ, Mills GB, Hennessy BT. Stordal B, et al. Mol Oncol. 2013 Jun;7(3):567-79. doi: 10.1016/j.molonc.2012.12.007. Epub 2013 Jan 31. Mol Oncol. 2013. PMID: 23415752 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous